title: [Intravesical therapy: Influence on superficial bladder cancer recurrence].
abstract: OBJECTIVE
  To review the influence of various intravesical treatments on superficial bladder cancer recurrence.
  
  
  METHODS
  We retrospectively reviewed 473 superficial bladder neoplasias. Based on diagnosis and transurethral resection of bladder tumor (TUR BT), and depending on pathology, we proposed different adjuvant treatment and follow-up schemes.
  
  
  RESULTS
  The following factors were independent risk factors for a longer recurrence-free time: intravesical instillations, high dose BCG, and maintenance therapy in comparison to induction.
  
  
  CONCLUSIONS
  The use of intravesical instillations independently increases the time to recurrence. It was demonstrated that recurrence was significantly later when high dose BCG and maintenance therapy were employed.
authors.affiliation: Servicio de Urología I, Hospital Central de Asturias, Oviedo, Asturias, España. jgrmed@hotmail.com
authors.forename: Jorge
authors.initials: J
authors.lastname: García Rodríguez
authors.forename: Jesús María
authors.initials: JM
authors.lastname: Fernández Gómez
authors.forename: Safwan
authors.initials: S
authors.lastname: Escaf Barmadah
authors.forename: Roberto Carlos
authors.initials: RC
authors.lastname: González Alvarez
authors.forename: Antonio
authors.initials: A
authors.lastname: Jalón Monzón
authors.forename: Francisco Javier
authors.initials: FJ
authors.lastname: Martínez Gómez
authors.forename: Alberto
authors.initials: A
authors.lastname: Sánchez Trilla
authors.forename: Javier
authors.initials: J
authors.lastname: Regadera Sejas
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000283:Administration, Intravesical; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001500:BCG Vaccine / Q000008:administration & dosage*; D006801:Humans; D016685:Mitomycin / Q000008:administration & dosage*; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D012189:Retrospective Studies; D013997:Time Factors; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000517:prevention & control*
chemical_list: D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D001500:BCG Vaccine; D016685:Mitomycin